Nasdaq: $30.39 (+2.53) | AIM: £4.26 (+0.12)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
監管信息公告, 腫瘤學 / 免疫學 | 2008-02-29

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate